CoverageForm 410-K10-Q8-K13D13G13F

ICAD · Icad Inc - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Income Statement

Line itemQ1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23Q3 '23Q2 '23Q1 '23Q4 '22
Revenue$4.87M-$4.07M$5.03M$4.95M--$5.87M$5.78M-
Cost of Revenue$685.0K-$583.0K$812.0K$841.0K-$552.0K$1.52M$1.65M-
Gross Profit$4.19M-$3.63M$4.22M$4.11M-$3.52M$4.35M$4.13M-
R&D$1.48M-$1.93M$1.76M$1.51M-$1.15M$1.26M$2.28M-
SG&A$2.25M-$1.81M$2.07M$1.90M-$2.04M$2.83M$2.86M-
Total Operating Expenses$5.32M-$5.65M$6.17M$5.55M-$4.74M$6.27M$8.05M-
D&A$56.0K-$56.0K$64.0K$63.0K-$56.0K$65.0K$55.0K-
Operating Income($1.13M)-($2.02M)($1.95M)($1.44M)-($1.22M)($1.92M)($3.92M)-
Interest Expense--$0$2.0K$0-$0$0$0-
Income Tax$0-$6.0K$8.0K$4.0K-$4.0K$4.0K$1.0K-
Net Income($833.0K)-($1.80M)($1.74M)($1.22M)-($1.37M)($1.75M)($3.78M)-
EPS - Basic($0.03)-($0.07)($0.07)($0.05)-($0.05)($0.07)($0.15)-
EPS - Diluted----------

Balance Sheet

Line itemQ1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23Q3 '23Q2 '23Q1 '23Q4 '22
Cash & Equivalents$20.03M$17.21M$18.79M$20.35M$20.28M$21.67M$19.05M$19.04M$19.66M$21.31M
Accounts Receivable$6.63M$7.21M$5.42M$5.38M$6.51M$6.39M$4.87M$5.75M$7.38M$8.90M
Inventory$694.0K$756.0K$689.0K$702.0K$750.0K$917.0K$992.0K$4.25M$4.87M$5.39M
Accounts Payable$1.14M$1.11M$422.0K$501.0K$635.0K$712.0K$1.10M$857.0K$1.89M$1.97M
Current Assets$28.12M$26.43M$26.11M$27.82M$29.04M$29.68M$32.34M$31.34M$34.20M$38.24M
Total Assets$39.47M$37.54M$37.11M$38.94M$40.40M$41.42M$45.83M$44.83M$47.52M$51.70M
Current Liabilities$7.69M$7.56M$6.50M$6.56M$6.16M$6.75M$11.41M$11.89M$12.88M$13.45M
Long-term Debt----------
Total Liabilities$8.68M$8.86M$7.73M$7.98M$7.93M$8.00M$14.79M$14.66M$15.81M$16.80M
Stockholders' Equity$30.79M$28.68M$29.37M$30.96M$32.46M$33.42M$31.04M$30.17M$31.71M$34.90M
Retained Earnings($278.13M)($277.30M)($276.44M)($274.64M)($272.90M)($271.68M)($273.74M)($272.36M)($270.61M)($266.84M)

Cash Flow

Line itemQ1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23Q3 '23Q2 '23Q1 '23Q4 '22
Operating Cash Flow$60.0K---($1.18M)---($1.53M)-
Investing Cash Flow$431.0K---($206.0K)---($122.0K)-
Financing Cash Flow$0-------$0-
CapEx$2.0K---$106.0K---$122.0K-
Free Cash Flow$58.0K---($1.29M)---($1.65M)-

Ratios

MetricQ1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23Q3 '23Q2 '23Q1 '23Q4 '22
Profitability
Gross margin85.9%-89.2%83.9%83.0%--74.2%71.5%-
Operating margin-23.2%--49.5%-38.7%-29.1%---32.8%-67.9%-
EBITDA margin-22.0%--48.1%-37.5%-27.8%---31.7%-67.0%-
Net margin-17.1%--44.2%-34.6%-24.7%---29.8%-65.4%-
Free cash flow margin1.2%----26.0%----28.6%-
FCF / Net income-0.07---1.05---0.44-
R&D / Revenue30.3%-47.3%35.1%30.4%--21.5%39.5%-
SG&A / Revenue46.2%-44.3%41.2%38.4%--48.3%49.5%-
Effective tax rate----------
Return on assets-2.1%--4.9%-4.5%-3.0%--3.0%-3.9%-8.0%-
Return on equity-2.7%--6.1%-5.6%-3.8%--4.4%-5.8%-11.9%-
Return on invested capital----------
Liquidity
Current ratio3.663.504.024.244.714.402.832.642.662.84
Quick ratio3.573.403.914.134.594.262.752.282.282.44
Cash ratio2.602.282.893.103.293.211.671.601.531.58
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----974.0x------
Equity multiplier1.281.311.261.261.241.241.481.491.501.48
Liabilities / Assets0.220.240.210.200.200.190.320.330.330.32
Efficiency
Asset turnover0.12-0.110.130.12--0.130.12-
Inventory turnover0.99-0.851.161.12-0.560.360.34-
Days sales outstanding496d-485d391d480d--358d466d-
Days inventory outstanding370d-431d316d326d-656d1023d1078d-
Days payable outstanding605d-264d225d276d-726d206d418d-
Cash conversion cycle261d-652d481d530d--1174d1126d-
Valuation
P / E----------
P / B----------
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)-1.6%---14.3%-14.3%---22.6%-23.2%-
Revenue CAGR (3y)-13.5%--24.2%-13.7%-16.9%--1.8%-4.1%-
Revenue CAGR (5y)-5.7%--12.3%-7.3%-6.1%---1.8%-2.8%-
Gross profit growth (YoY)1.8%-3.2%-3.0%-0.4%--19.5%-20.8%-22.3%-
Operating income growth (YoY)21.7%--65.3%-1.3%63.3%-69.2%38.2%-11.4%-
Net income growth (YoY)31.8%--31.1%0.6%67.7%-64.8%43.9%-6.6%-
EPS growth (YoY)----------
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----22.1%---64.1%-
FCF CAGR (5y)----------
Book value growth (YoY)-5.2%-14.2%-5.4%2.6%2.4%-4.3%-17.6%-26.4%-27.5%-25.0%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2024-12-31.

Product / service

$19.61M total
Products And Perpetual Licenses$7.33M · 37.4%
Services And Support$7.08M · 36.1%
Subscription Term Licenses$4.97M · 25.4%
Cloud Subscriptions$234.0K · 1.2%

Geographic

$2.70M total
Non Us$2.70M · 100.0%

Peer comparison

Same SIC group: Surgical & Medical Instruments & Apparatus

CompanyRevenue (last FY)Net marginROE
BSX$20.07B14.4%12.0%
LMAT$249.60M23.1%14.7%
TNDM$1.01B-20.2%-131.9%
SYK$25.12B12.9%14.5%
MMM$24.95B13.0%69.1%

Comparing ICAD INC against the 5 most active filers in the same SIC group.